Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CCCC | US
-0.05
-0.92%
Healthcare
Biotechnology
30/06/2024
04/10/2024
5.38
5.48
5.48
5.18
C4 Therapeutics Inc. a clinical-stage biopharmaceutical company develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer neurodegenerative conditions and other diseases. Its lead product candidate is CFT7455 an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634 an orally bioavailable BiDAC degrader of BRD9 a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946 an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma non-small cell lung cancer (NSCLC) colorectal cancer and other solid malignancies; CFT8919 an orally bioavailable allosteric and mutant-selective BiDAC degrader of epidermal growth factor receptor or EGFR with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown Massachusetts.
View LessLow Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
32.1%1 month
76.3%3 months
89.9%6 months
76.7%-
-
1.65
0.28
0.18
-0.42
7.24
-
-114.69M
373.04M
373.04M
-
-178.59
-
350.70
-44.87
10.05
20.91
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.38
Range1M
2.66
Range3M
3.31
Rel. volume
0.45
Price X volume
2.93M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
LRMR | LRMR | Biotechnology | 6.65 | 408.81M | 5.72% | n/a | 2.65% |
Sage Therapeutics Inc | SAGE | Biotechnology | 6.64 | 405.37M | -4.87% | n/a | 0.22% |
Theravance Biopharma Inc | TBPH | Biotechnology | 8.1 | 396.27M | -1.34% | n/a | 24.09% |
Voyager Therapeutics Inc | VYGR | Biotechnology | 7.04 | 383.91M | 20.96% | 21.67 | 13.99% |
Biomea Fusion Inc. Common Stock | BMEA | Biotechnology | 10.48 | 379.48M | 3.46% | n/a | 9.95% |
ZVRA | ZVRA | Biotechnology | 7.2 | 378.85M | 1.12% | n/a | 183.10% |
Anika Therapeutics Inc | ANIK | Biotechnology | 24.99 | 369.77M | -0.12% | n/a | 13.35% |
Fate Therapeutics Inc | FATE | Biotechnology | 3.22 | 366.69M | 0.31% | n/a | 25.33% |
ITOS | ITOS | Biotechnology | 10.02 | 365.95M | 2.04% | n/a | 0.83% |
Corvus Pharmaceuticals Inc | CRVS | Biotechnology | 5.64 | 352.79M | 6.82% | n/a | 1.37% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.42 | 0.76 | Cheaper |
Ent. to Revenue | 7.24 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 1.65 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 89.93 | 74.67 | Riskier |
Debt to Equity | 0.28 | -1.82 | Expensive |
Debt to Assets | 0.18 | 0.26 | Cheaper |
Market Cap | 373.04M | 3.73B | Emerging |